Eiger BioPharmaceuticals, Inc.

Passed

Class Action Period:
March 10, 2021 - October 04, 2022

Lead Plaintiff Deadline:
January 09, 2023

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

(i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until January 09, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.